Related Experiment Video
Updated: Mar 15, 2026
06:32
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
Published on: August 18, 2023
3.2K
Towards tumor immunodiagnostics.
Helen Kourea1, Vassiliki Kotoula2
1Department of Pathology, University Hospital of Patras, Rion, Greece ;
Annals of Translational Medicine
|August 27, 2016
Summary
Immunodiagnostic markers, including morphological and immunophenotypic assessments, can predict cancer prognosis and treatment response. However, challenges remain in their clinical application for personalized medicine.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Immunodiagnostic markers are crucial for predicting prognosis and response to immunomodulatory drugs in cancer.
- These markers can be cell-specific (morphological, immunophenotypic) or tumor-tissue-specific (gene expression, genotype).
Purpose of the Study:
- To discuss the biological nature of immunodiagnostic markers.
- To explore their potential clinical relevance in cancer care.
- To identify limitations hindering their widespread clinical application.
Main Methods:
- Evaluation of cell-specific markers via hematoxylin & eosin (H&E) staining for morphology and immunohistochemistry (IHC) for immunophenotyping.
- Assessment of tumor-tissue-specific markers using gene expression profiles and large-scale genotyping (e.g., next-generation sequencing [NGS]).
Main Results:
- Cell-specific markers offer insights into tumor-infiltrating immune cells.
- Tumor-tissue-specific markers provide comprehensive genomic and transcriptomic information.
- Despite potential, current shortcomings impede clinical utility.
Conclusions:
- Immunodiagnostic markers hold significant promise for personalized cancer therapy.
- Further research is needed to overcome existing challenges and facilitate clinical translation.
